RBF197 (RBF-197) is a novel highly potent and selective eIF4A inhibitor, inhibits human eIF4A helicase activity with IC50 of 55.2 pM.
RBF197 potentially binds to the same pockets as Rocaglamide A (RocA).
RBF197 blocks cell proliferation against a panel of DLBCL cell lines using WST-1 assay (OCILy3 cell, IC50=0.4 uM), including SUDHL2 cell (IC50=3.2 uM), which harbors a mutation in A20, SOCS1, and TP53.
RBF197 decreases overall translation and eIF4A1 dependent pathway proteins in double-hit lymphoma.
RBF197 (1 uM and 3 uM) decreases protein levels of eIF4A, but not eIF4E1 and the transcript levels of eIF4A1, in DLBCLs RC (GCB, Double-Hit) and OCI-LY3 (ABC) cell lines.
